Nektar Therapeutics

NKTRNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
39.91 USD
↘ 2.31 (5.47%)AT CLOSE (03:59 PM EDT)
40.47
↗ 0.56 (1.41%)
POST MARKET (AS OF 06:05 PM EDT)
Post Market
AS OF 06:05 PM EDT
40.47
↗ 0.56 (1.41%)
🟢Market: OPEN

NKTR is currently priced at $40.47. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place NKTR at a fair price relative to peers.

Technical & fundamental data as of Oct 6, 2026.

Open?$42.44
High?$42.44
Low?$39.34
Prev. Close?$42.22
Volume?2.0M
Avg. Volume?1.4M
VWAP?$40.31
Rel. Volume?1.38x
Bid / Ask
Bid?$33.43 × 100
Ask?$46.57 × 100
Spread?$13.14
Midpoint?$40.00
Valuation & Ratios
Market Cap?1.4B
Shares Out?34.1M
Float?33.2M
Float %?97.4%
P/E Ratio?N/A
P/B Ratio?1.60
EPS?-$4.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
63
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.nektar.com
Listed
1994-05-03
Address
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
2
Momentum?
71
Short Sent.?
50
Piotroski F-Score?2/9Weak
Altman Z-Score?-0.05Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.25%High
Short Interest?5.7M
Days to Cover?7.6
Free Float33.2M
Avg Daily Volume757.2K
Settlement Date2026-09-15
Financial Health
Current Ratio?10.42Strong
Quick Ratio?10.42Strong
Cash Ratio?0.55Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
85
1.60CHEAP▾
P/S?
Peers
100
S&P
3
26.41HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-10.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
25.69HIGH▾
Returns & Efficiency
ROE?
S&P
8
-17.4%WEAK▾
ROA?
S&P
3
-14.4%WEAK▾
Cash Flow & Enterprise
FCF?$-234032000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist